Niklas Landberg

466 total citations
17 papers, 289 citations indexed

About

Niklas Landberg is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Niklas Landberg has authored 17 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Hematology, 6 papers in Immunology and 5 papers in Oncology. Recurrent topics in Niklas Landberg's work include Acute Myeloid Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (9 papers) and CAR-T cell therapy research (3 papers). Niklas Landberg is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (9 papers) and CAR-T cell therapy research (3 papers). Niklas Landberg collaborates with scholars based in Sweden, United States and Australia. Niklas Landberg's co-authors include Marianne Rissler, Helena Ågerstam, Henrik Lilljebjörn, Thoas Fioretos, Carl Sandén, Sofia von Palffy, Maria Askmyr, Marcus Järås, Johan Richter and Satu Mustjoki and has published in prestigious journals such as Nature Communications, Blood and PLoS ONE.

In The Last Decade

Niklas Landberg

15 papers receiving 286 citations

Peers

Niklas Landberg

HEMAT

IMMUN

ONCOL

GENET

Shady Adnan Awad Finland

Jennifer Cassels United Kingdom

Jessie J.F. Medeiros Canada

Giulia Biancon United States

Parimala Sonika Godavarthy Germany

Bárbara da Costa Reis Monte-Mór Brazil

Kathleen Hueneman United States

Magdalena Hinterbrandner Switzerland

Katherine E. Lindblad United States

Carl Sandén Sweden

Shady Adnan Awad Finland

Niklas Landberg

174 ×1.2

HEMAT

81 ×0.7

60 ×0.8

IMMUN

65 ×0.9

ONCOL

124 ×2.0

GENET

Citations per year, relative to Niklas Landberg Niklas Landberg (= 1×) peers Shady Adnan Awad

Countries citing papers authored by Niklas Landberg

Since Specialization

Citations

This map shows the geographic impact of Niklas Landberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niklas Landberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niklas Landberg more than expected).

Fields of papers citing papers by Niklas Landberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niklas Landberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niklas Landberg. The network helps show where Niklas Landberg may publish in the future.

Co-authorship network of co-authors of Niklas Landberg

This figure shows the co-authorship network connecting the top 25 collaborators of Niklas Landberg. A scholar is included among the top collaborators of Niklas Landberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niklas Landberg. Niklas Landberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Lilljebjörn, Henrik, Rasmus Henningsson, Marianne Rissler, et al.. (2025). The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes. Nature Communications. 16(1). 10592–10592.

Sandén, Carl, Niklas Landberg, Shruti Daga, et al.. (2025). Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia. Nature Cancer. 6(11). 1821–1838.

Landberg, Niklas, Thomas Köhnke, Yang Feng, et al.. (2023). IDH1 -Mutant Preleukemic Hematopoietic Stem Cells Can Be Eliminated by Inhibition of Oxidative Phosphorylation. Blood Cancer Discovery. 5(2). 114–131. 9 indexed citations

Linde, Miles H., Amy C. Fan, Thomas Köhnke, et al.. (2023). Reprogramming Cancer into Antigen-Presenting Cells as a Novel Immunotherapy. Cancer Discovery. 13(5). 1164–1185. 33 indexed citations

Thomas, Danièl, Manhong Wu, Yusuke Nakauchi, et al.. (2022). Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability. Cancer Discovery. 13(2). 496–515. 39 indexed citations

Palffy, Sofia von, Carl Sandén, Anna M. Blom, et al.. (2022). The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML. Blood Advances. 7(7). 1204–1218. 6 indexed citations

Landberg, Niklas, Yusuke Nakauchi, Amy C. Fan, et al.. (2022). Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML. Blood. 140(Supplement 1). 2234–2235. 2 indexed citations

Orsmark‐Pietras, Christina, Niklas Landberg, Fryderyk Lorenz, et al.. (2021). Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR‐ABL1, a Swedish population‐based study. Genes Chromosomes and Cancer. 60(6). 426–433. 8 indexed citations

Sandén, Carl, Henrik Lilljebjörn, Christina Orsmark‐Pietras, et al.. (2020). Clonal competition within complex evolutionary hierarchies shapes AML over time. Nature Communications. 11(1). 579–579. 21 indexed citations

10.

Palffy, Sofia von, Niklas Landberg, Carl Sandén, et al.. (2019). A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells. Haematologica. 105(8). 2095–2104. 9 indexed citations

11.

Landberg, Niklas, Sofia von Palffy, Maria Askmyr, et al.. (2017). CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting. Haematologica. 103(3). 447–455. 51 indexed citations

12.

Askmyr, Maria, Sofia von Palffy, Nils Hansen, et al.. (2017). Transgenic expression of human cytokines in immunodeficient mice does not facilitate myeloid expansion of BCR-ABL1 transduced human cord blood cells. PLoS ONE. 12(10). e0186035–e0186035. 4 indexed citations

13.

Landberg, Niklas, Arta Dreimane, Marianne Rissler, Rolf Billström, & Helena Ågerstam. (2017). Primary cells in BCR/FGFR1‐positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib. European Journal Of Haematology. 99(5). 442–448. 15 indexed citations

14.

Ågerstam, Helena, Nils Hansen, Sofia von Palffy, et al.. (2016). IL1RAP antibodies block IL-1–induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood. 128(23). 2683–2693. 70 indexed citations

15.

Askmyr, Maria, Helena Ågerstam, Henrik Lilljebjörn, et al.. (2014). Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells. Blood Cancer Journal. 4(12). e269–e269. 11 indexed citations

16.

Askmyr, Maria, Helena Ågerstam, Henrik Lilljebjörn, et al.. (2014). Modeling Chronic Myeloid Leukemia in Immunodeficient Mice Reveals an Inflammatory State with Expansion of Aberrant Mast Cells and Accumulation of Pre B Cells. Blood. 124(21). 3132–3132. 1 indexed citations

17.

Hansen, Nils, Helena Ågerstam, Martin Wahlestedt, et al.. (2012). SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function. Leukemia. 27(1). 130–135. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact